Side-by-side · Research reference
IGF-DESvsVesugen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED8/60 cited
BAnimal-MechanisticHUMAN-REVIEWED5/43 cited
IGF-DES
IGF-1 Analogue · Truncated N-Terminal
~10×Potency vs IGF-1
ReducedIGFBP binding
ResearchStatus
Injection (local or systemic) · Research protocols onlyBredehöft 2008
Vesugen
Bioregulatory Tripeptide · Vascular Endothelium
3 AATripeptide
Endothelin-1 ↓Atherosclerotic tissue
Ki-67 ↑Aged endothelium
SQ / IM · Protocol varies
01Mechanism of Action
Parameter
IGF-DES
Vesugen
Primary target
IGF-1 receptor (IGF1R)Shields 2007
Vascular endothelial cell nucleus — MKI67 gene promoter
Pathway
IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation
KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑
Downstream effect
Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation
Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016Khavinson 2014
Feedback intact?
Unknown — no human endocrine feedback data
Not applicable — does not operate via hormone axis
Origin
Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008
Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator
Antibody development
—
—
02Dosage Protocols
Parameter
IGF-DES
Vesugen
Research dose range
10–100 ng/mL (in vitro); μg doses (animal models)
Highly context-dependent; no standardized human protocol.
—
Route
Subcutaneous or intramuscular (local injection favored)
Local delivery maximizes tissue-specific uptake.
Subcutaneous or intramuscular
Frequency
Variable — daily to multiple times daily in research
Not specified in available literature
Evidence basis
Animal models + in vitro only
Animal models (atherosclerosis, restenosis, aging) · Russian case series
Human data
None — no clinical trials
—
Half-life
Shorter than IGF-1 due to reduced IGFBP binding
Rapid tissue uptake, limited systemic circulation.
Not reported
Tripeptides typically cleared rapidly.
Standard dose (reported)
—
Not standardised — Russian clinical case series
Protocols vary; no FDA-approved regimen.
Duration
—
Case series report treatment courses in elderly arterial insufficiency
03Metabolic / Fat Loss Evidence
Parameter
IGF-DES
Vesugen
Primary mechanism
Indirect via muscle hypertrophy → metabolic rate elevation
—
Direct lipolysis
Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic
—
Prostate model
Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002
Context-specific anti-proliferative effect, not fat loss.
—
04Side Effects & Safety
Parameter
IGF-DES
Vesugen
Hypoglycemia risk
Theoretical — IGF-1 axis enhances glucose uptake
—
Mitogenic risk
Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002
—
Injection site reaction
Expected — erythema, irritation, local swelling
—
Edema / Fluid retention
Possible via sodium retention (IGF-1 axis effect)
—
Human safety data
Absent — no human trials, all effects theoretical or extrapolated
—
Unknown long-term effects
No chronic dosing studies in humans; endocrine, metabolic consequences unknown
—
Reported adverse events
—
None documented in available abstracts
Injection site
—
Assumed minimal — typical for small peptides
Long-term safety
—
Unknown — no long-term RCT data
Epigenetic mechanism risk
—
Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised
Absolute Contraindications
IGF-DES
- ·Active malignancy or history of cancer (mitogenic risk)
- ·Pregnancy / lactation (no safety data)
- ·Hypoglycemia disorders
Vesugen
—Relative Contraindications
IGF-DES
- ·Diabetes mellitus (unpredictable glucose effects)
- ·Renal or hepatic impairment (clearance unknown)
- ·Edema-prone conditions (heart failure, nephrotic syndrome)
Vesugen
- ·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context
05Administration Protocol
Parameter
IGF-DES
Vesugen
1. Research context only
Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.
Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.
2. Reconstitution (if lyophilized)
Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.
Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.
3. Injection site
Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.
No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.
4. Timing
Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.
Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).
5. Needle gauge
27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.
—
6. Monitoring
Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.
—
06Stack Synergy
IGF-DES
+ BPC-157
ModerateDes(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- BPC-157
- 250–500 mcg SQ, daily or twice daily
- Frequency
- Daily or per research protocol
- Primary benefit
- Accelerated muscle repair, enhanced hypertrophy, connective tissue support
+ TB-500
ModerateTB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- TB-500
- 2–5 mg SQ, 2× weekly
- Frequency
- Per research cycle
- Primary benefit
- Muscle hypertrophy, injury recovery, vascular support
Vesugen
+ Thymalin
Multi-pathwayBoth from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.
- Vesugen
- Per protocol (SQ/IM)
- Thymalin
- Per protocol (SQ/IM)
- Frequency
- Sequential or concurrent per geroprotective protocol
- Primary benefit
- Multi-system age-related decline mitigation (vascular + immune)